Earnings ·
TriSalus reports Q3 revenue of $12.9 million and raises full-year guidance to $46M-$48M
TLSIWTriSalus Life Sciences, Inc.
TriSalus Life Sciences reported third-quarter revenue of $12.9 million, an 11.3% increase year-over-year, driven by higher TriNav unit sales. The company raised its full-year 2026 revenue guidance to a range of $46 million to $48 million. Operating losses narrowed to $7.7 million from $9.0 million in the prior-year period, while net loss attributable to common stockholders was $8.9 million compared to $41.3 million previously, largely due to non-recurring preferred stock conversion charges in 2025. The firm also announced FDA clearance for TriNav Advance and favorable CMS reimbursement policies effective January 2027 that increase Medicare payment rates for its procedures. TriSalus Life Sciences is an oncology-focused medical technology company developing pressure-enabled drug delivery systems and investigational immunotherapies for solid tumors.